Novo Nordisk nach Split WKN: A3EU6F ISIN: DK0062498333 Kürzel: NOV Forum: Aktien User: Coronaprofiteur

Die Wochenkerze sieht katastrophal aus

Jeden Tag rot hier das gibt’s doch nicht

Auch heute werden wir wohl nicht grün schliessen. :(

"ist wohl auch" 😂 Entweder sie sind es oder sind es nicht.

https://www.finanztrends.de/novo-nordisk-aktie-uebersehen-anleger-etwas/ klingt eigentlich alles recht gut

Nicht unbedingt noch mehr. Aber das hält den Kurs vielleicht auch unten

Trotzdem ärgerlich wenn man hier wohl aufs falsche Pferd gesetzt hat. Jeder Anstieg wird sofort wieder abverkauft.

Das USA-Geschäft ist sicher sehr wichtig, aber nicht alles. Es bleiben der Nahe und der Ferne Osten – und natürlich Europa.

noch mehr? Das ist doch schon unter die Räder gekommen......

Sehe ich auch so. Man muss wohl erstmal sehen was jetzt kommt. Da Trump mit Amerika first Eli Lily wohl eher in Schutz nehmen würde könnte Novo mit Trump und RFK eher unter die Räder kommen

ja die besten Zeiten sind wohl vorbei. Trotzdem sehe ich die 100 tendenziell schon. Grad im Vergleich zum Chart von Eli Lilly. Da gabs eigentlich kaum Rücksetzer nach heftigem Anstieg. Novo hat 50% des Anstiegs schon wieder abgegeben in nem halben Jahr.

Weil sie es konnten. Hohe Nachfrage wenig Angebot. Wird aber auch nicht so bleiben

So sollen sich RFK und Musk erstmal prügeln und wir sehen weiter. Aber das sorgt sicher für Unsicherheit

Auszug Kennedy and his MAHA circle are not fans of the weight-loss drugs that have become hugely popular and supercharged shares of Zepbound maker Eli Lilly & Co. and Denmark’s Novo Nordisk A/S, the maker of Ozempic and Wegovy. “When I’m working in the next administration, I will address our sick food system — and the corrupt government agencies — to help make our country healthy again,” Kennedy wrote on X before the presidential election. “In the meantime, perhaps we should consider replanting the kitchen garden before sending more money to Denmark,” he said. Kennedy later walked back those remarks, saying in a CNBC interview that the drugs “have a place,” but that the first line of defense against obesity and other chronic diseases “should be lifestyle, it should be eating well.” If Kennedy were to attempt to revoke approvals for Ozempic and other drugs like it, known as GLP-1s, it’d likely be a legal nightmare. But he could move to limit access to the medications. Last year, the Biden administration issued a proposal to cover obesity drugs through Medicare, the government health insurance program for people 65 and older. The onus is on the Trump administration to finalize it. ADVERTISEMENT Calley Means, a health entrepreneur and top Kennedy adviser, has railed against the popularity of Ozempic and criticized the Biden administration’s proposal. At the same time, Elon Musk, a close Trump adviser, has touted the benefits of weight-loss drugs, going so far as to say “nothing would do more to improve the health, lifespan and quality of life for Americans” than making GLP-1 drugs “super low cost to the public.” It’s an important issue for Lilly and Novo, who are still pushing the Trump administration to finalize the rule. Another key figure in decisions on Medicare reimbursement for the drugs is Mehmet Oz, the celebrity doctor whom Trump picked to lead the Centers for Medicare and Medicaid Services. “My argument to Mehmet Oz is that if you want to protect Medicare costs in 10 years, have ACA and Medicare plans list these drugs now,” Lilly CEO Dave Ricks said in an interview with Bloomberg in January, referring to the Affordable Care Act. “We know so much about how much cost savings there will be downstream in heart disease and other conditions.” Ricks is also asking the Trump administration to crack down on the booming market for copycat weight-loss drugs. So-called compounding pharmacies have capitalized on a legal policy that allows copies of drugs to be made when the brand-name ones are in shortage. Widespread shortages of Novo and Lilly’s drugs last year allowed cheaper, copycat versions to proliferate. ADVERTISEMENT Ricks has blamed the Biden administration for not doing enough to stop it. “We’re counting on the new administration to enforce this,” Ricks told Fox Business last week. However, there's signs it may not go the way pharma had hoped. “Our sense (reading in-between the lines), is that the RFK-led HHS will take a fairly lenient stance with respect to the GLP compounders provided the drugs are seen as safe,” Mizuho health-care sector specialist Jared Holz said in a note after Kennedy was confirmed, noting the recent rise in shares of Hims & Hers Health Inc., which sells compounded shots.

ich mein im Grunde hat er ja Recht. Kann man nicht abstreiten.... Ich würde mir diese Spritze auch nicht laufend setzen wollen. Warum kostet die in USA eig viel mehr als in Dtld.? Das ist doch auch ne Frechheit.

https://www.yahoo.com/news/rfk-jr-power-means-vaccines-191051529.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAMTrbOQxXl6_0XT9enu-tQKqsqzZ_fU4GZ4N6Y9HERuclZzNwOs6D7xFWEj_UwO3WN-5ITfAVetqKerZF1nitZIPzEdf3mHDmNDOy-UHMp_0-NWWdPG7ziZoS815liEFsE6sXVTx37A8zKKDYDKZTFebk-Egj5ZBumxVI7ZH_ogO